skip to Main Content

Access to Hepatitis C Treatment Through State AIDS Drug Assistance Programs (ADAPs)

By Tracy Swan

May 31, 2007

The Henry J. Kaiser Family Foundation and the National Association of State and Territorial AIDS Directors (NASTAD) released the 2007 National ADAP Monitoring Project Annual Report on April 10th, 2007.

Access to hepatitis C treatment is crucial for HIV/HCV coinfected people. Although hepatitis C can be treated, HCV-associated end-stage liver disease has become a leading cause of death among HIV-positive people in the US.

Although funding shortfalls and increasing need mean that the majority of ADAPs are currently unable to provide pegylated interferon and ribavirin, some are still covering HCV treatment and/or adjunctive therapies used to manage side effects (see table of State ADAP Coverage below). Some State ADAPs offer hepatitis A (HAV) and hepatitis B (HBV) vaccines, which are recommended for people with HIV and hepatitis C who are susceptible to these viruses.

If your State ADAP does not cover hepatitis C treatment, you may be able to obtain it through patient assistance programs sponsored by Roche and Schering.

  • Roche Patient Assistance Foundation: 1-877-75ROCHE (877-757-6243)
  • Schering Commitment to Care (1-800-521-7157)
  • Direct link to Schering’s Commitment to Care Application (accessed May 21 2007): www.schering-plough.com/pdf/commitapp.pdf

 

State ADAP Coverage: Hepatitis A (HAV) & Hepatitis B (HBV) Vaccines, Hepatitis C Treatment, Growth Factors, & Selective Serotonin Reuptake Inhibitors (SSRIs) as of May 2007

State

IFN (PEG, Standard, Consensus)

RBV

SSRIs/
Other*

Epoetin-
Alfa

Filgrastim

HAV & HBV Vaccine

Waiting List/ Other Cost Containment

ALABAMA

X

Capped enrollment
ALASKA

X

ARIZONA PEG-IFN

X

X

X

X

X

ARKANSAS
CALIFORNIA Standard IFN

X

X

X

X

X

COLORADO
CONNECTICUT PEG-IFN

X

X

X

X

DELAWARE PEG-IFN

X

X

X

X

DISTRICT OF COLUMBIA Standard IFN

X

X

X

FLORIDA

X

X

X

Lowered income eligibility
GEORGIA

X

HAWAII

X

X

X

IDAHO Cost containment anticipated before 3/31/08
ILLINOIS Standard IFN
INDIANA

X

Capped enrollment
IOWA
KANSAS
KENTUCKY

X

Cost containment anticipated before 3/31/08
LOUISIANA
MAINE
MARYLAND PEG-IFN, Standard IFN

X

X

X

MASSACHUSETTS All FDA-approved drugs are covered**
MICHIGAN PEG-IFN, Standard IFN

X

X

X

X

X

Formulary management
MINNESOTA

X

MISSISSIPPI PEG-IFN

X

X

Lowered medical eligibility
MISSOURI

X

X

MONTANA

X

X

X

Waiting list
NEBRASKA

X

X

X

NEVADA

X

X

NEW HAMPSHIRE

X

X

X

Cost containment anticipated before 3/31/08
NEW JERSEY All FDA-approved drugs are covered**
NEW MEXICO

X

X

X

NEW YORK PEG-IFN

X

X

X

X

X

NORTH CAROLINA

X

NORTH DAKOTA

X

X

OHIO

X

X

OKLAHOMA
OREGON

X

X

PENNSYLVANIA PEG-IFN

X

X

X

X

PUERTO RICO PEG-IFN, Standard IFN

X

X

X

X

Waiting List
RHODE ISLAND PEG-IFN, Standard IFN

X

X

Lowered income eligibility; additional cost containment anticipated by 3/31/08
SOUTH CAROLINA

X

X

Waiting List; reduced formulary; capped enrollment
SOUTH DAKOTA

X

X

TENNESSEE PEG-IFN

X

X

X

TEXAS
U.S. VIRGIN ISLANDS Client cost sharing; additional cost containment anticipated by 3/31/08
UTAH
VERMONT

X

X

X

VIRGINIA PEG-IFN

X

X

X

WASHINGTON PEG-IFN, Standard IFN

X

X

X

X

WEST VIRGINIA
WISCONSIN PEG-IFN

X

X (Elavil only)

X

WYOMING

X

X

* May include anti-anxiety agents, anti-depressants, anti-psychotics, mood stabilizers, and other psychiatric medications.

**With certain exclusions.

Sources:

  1. Henry J. Kaiser Family Foundation, National Alliance of State and Territorial AIDS Directors (NASTAD). National ADAP Monitoring Project, Annual Report, April 2007. ADAP Formularies. Available on-line at: www.kff.org/hivaids/7619.cfm (accessed on May 9th, 2007).
  2. NASTAD. ADAP Watch. April 2007. Available on-line at: www.nastad.org/Publications/adapwatch.aspx (accessed on May 9th, 2007).

Thanks to Britten Ginsburg, Murray Penner, Beth Crutsinger-Perry and Chris Taylor at NASTAD.

Tracy Swan is TAG’s Coinfection Project Director.

 

Back To Top